Antidepressant Adherence and Medical Resource Use Among Managed Care Patients With Anxiety Disorders
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This study evaluated adherence with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) among patients who newly initiated therapy for anxiety with or without comorbid depression; the study also quantified the health-related economic consequences of nonadherence. METHODS: A large managed care database was used to gather retrospective data for patients with anxiety disorders who had a prescription for an antidepressant between July 1, 2001, and December 31, 2002. The relationship between antidepressant adherence and medical resource utilization was assessed; the analysis controlled for age, gender, utilization of mental health specialty care, change in medication, whether the dosage was titrated, costs in the six months before the prescription for an antidepressant, and comorbid physical conditions. RESULTS: Of the 13,085 patients with anxiety diagnoses who met the criteria for study inclusion, 57 percent were nonadherent to antidepressant therapy at six months. Patients who received mental health specialty care were more likely than those who did not receive such care to be adherent to therapy (48.5 percent compared with 40.7 percent; p<.001). Those with dual diagnoses of anxiety and depression were more likely than those with anxiety alone to be adherent to therapy (46.8 percent compared with 40.2 percent; p<.001). Those with a coded diagnosis of posttraumatic stress disorder had the highest medical costs. Patients with anxiety and depression had significantly higher total costs than patients with anxiety alone. Adherent patients who did not have a change in medication or a titrated dosage had significantly lower medical costs than nonadherent patients; however, total costs (medical plus pharmacy) were similar. CONCLUSIONS: Nonadherence with antidepressant therapy in anxiety disorders is common, but mental health specialty care may be associated with improved adherence. Lower medical costs for adherent patients who did not have a change in medication or a titrated dosage offset the increase in pharmacy costs, resulting in total costs (medical plus pharmacy) that were similar to those of nonadherent patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695 · cited 2×
“The findings add to the current literature showing low rates of quality of pharmacotherapy among patients with anxiety disorders managed in primary care settings and overall low rates of adequate care provided to patients with anxiety disorders in the U.S. general population (26, 27 ).”
BackgroundThe economic burden of anxiety disorders in the 1990s
Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson, J. R. T., Ballenger, J. C., & Fyer, A. J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0702 · Cited by 1,242
Quality-of-Life Impairment in Depressive and Anxiety Disorders
Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1171 · Cited by 914
Katon, W. J., Roy-Byrne, P., Russo, J., & Cowley, D. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1098 · Cited by 171 · cited 2×
“These data are observational only and cannot speak to whether efforts directed at improving adherence would result in a cost offset—as has been seen in some studies ( 20 )—and improve health-related quality of life in a cost-effective fashion.”
BackgroundResultRoy-Byrne, P. P., Katon, W., Cowley, D. S., & Russo, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.869 · Cited by 158
Anxiety and Depression: Optimizing Treatments
Ballenger, J. C. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0301 · Cited by 83 · cited 1×
“A possible explanation for this finding may be that patients with comorbid anxiety and depression commonly have more severe symptoms and a poorer outcome than patients without comorbid depression and may thus require more aggressive treatment ( 30 ,31).”
Background
Cited by
Medication Adherence: A Review of the Literature and Implications for Clinical Practice
Julius, R. J., Novitsky, M. A., & Dubin, W. R. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000344917.43780.77 · Cited by 301
Bruce, J. M., Hancock, L. M., Arnett, P., & Lynch, S. (2010) · Journal of Behavioral Medicine · doi:10.1007/s10865-010-9247-y · Cited by 276
Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: A systematic review
Konnopka, A., Leichsenring, F., Leibing, E., & König, H.-H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.07.014 · Cited by 161
“On the other hand, all databases used by retrospective cohort studies were Table 2 Cost categories considered by cost-of-illness studies Study Direct cost Outpatient treatment Inpatient treatment Drugs Rehabilitations Em unit Edlund and Swan (1987) + − − − − Siegel et al. (1990) + − − − + Souetre et al. (1994) + + + −…”
BackgroundInfluentialMood disorders medications: predictors of nonadherence – review of the current literature
Pompili, M., Venturini, P., Palermo, M., Stefani, H., Seretti, M. E., Lamis, D. A., Serafini, G., Amore, M., & Girardi, P. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811976 · Cited by 120
A review of studies concerning treatment adherence of patients with anxiety disorders
Fontenelle, L., & Santana (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s23439 · Cited by 82
Metadata
- Authors
- Stein, M. B., Cantrell, C. R., Sokol, M. C., Eaddy, M. T., & Shah, M. B.
- Venue
- Psychiatric Services
- Published
- 2006-05-01
- Volume
- 57
- Issue
- 5
- Pages
- 673-680
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- OpenAlex
- W1988024727
- Cited by
- 91
- References
- 6
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.